RU2531510C2 - Модифицированные f протеины sv и способы их применения - Google Patents

Модифицированные f протеины sv и способы их применения Download PDF

Info

Publication number
RU2531510C2
RU2531510C2 RU2011128371/10A RU2011128371A RU2531510C2 RU 2531510 C2 RU2531510 C2 RU 2531510C2 RU 2011128371/10 A RU2011128371/10 A RU 2011128371/10A RU 2011128371 A RU2011128371 A RU 2011128371A RU 2531510 C2 RU2531510 C2 RU 2531510C2
Authority
RU
Russia
Prior art keywords
protein
rsv
modified
seq
mutated
Prior art date
Application number
RU2011128371/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2011128371A (ru
Inventor
Питер ПУШКО
Инюнь У
Майкл МАССАР
Е Лю
Гейл СМИТ
Бинь ЧЖОУ
Original Assignee
Новавакс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42310119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2531510(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новавакс, Инк. filed Critical Новавакс, Инк.
Publication of RU2011128371A publication Critical patent/RU2011128371A/ru
Application granted granted Critical
Publication of RU2531510C2 publication Critical patent/RU2531510C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2011128371/10A 2008-12-09 2009-12-09 Модифицированные f протеины sv и способы их применения RU2531510C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12112608P 2008-12-09 2008-12-09
US61/121,126 2008-12-09
US16907709P 2009-04-14 2009-04-14
US61/169,077 2009-04-14
US22478709P 2009-07-10 2009-07-10
US61/224,787 2009-07-10
PCT/US2009/067269 WO2010077717A1 (en) 2008-12-09 2009-12-09 Modified rsv f proteins and methods of their use

Publications (2)

Publication Number Publication Date
RU2011128371A RU2011128371A (ru) 2013-01-20
RU2531510C2 true RU2531510C2 (ru) 2014-10-20

Family

ID=42310119

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011128371/10A RU2531510C2 (ru) 2008-12-09 2009-12-09 Модифицированные f протеины sv и способы их применения

Country Status (23)

Country Link
US (7) US8715692B2 (https=)
EP (3) EP2370099B1 (https=)
JP (4) JP5813513B2 (https=)
KR (2) KR101691574B1 (https=)
CN (2) CN106146671B (https=)
AU (1) AU2009333484B2 (https=)
BR (1) BRPI0922867B8 (https=)
CA (1) CA2746228C (https=)
CY (2) CY1117757T1 (https=)
DK (2) DK2370099T3 (https=)
ES (3) ES2582005T3 (https=)
HR (2) HRP20160859T1 (https=)
HU (2) HUE029037T2 (https=)
IL (2) IL213450B (https=)
LT (1) LT3067064T (https=)
MX (4) MX345700B (https=)
PL (2) PL2370099T3 (https=)
PT (2) PT3067064T (https=)
RU (1) RU2531510C2 (https=)
SG (2) SG10201500161XA (https=)
SI (2) SI2370099T1 (https=)
SM (1) SMT202000411T1 (https=)
WO (1) WO2010077717A1 (https=)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160000902A1 (en) * 2003-07-11 2016-01-07 Novavax, Inc. Combination vaccine for respiratory syncytial virus and influenza
JP6046348B2 (ja) * 2008-11-18 2016-12-14 タケダ ヴァクシーンズ， インコーポレイテッド Ｒｓｖｆｖｌｐならびにその製造および使用の方法
PL2370099T3 (pl) 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
KR101847908B1 (ko) * 2010-11-05 2018-04-11 노바백스, 인코포레이티드 광견병 당단백질 바이러스-유사 입자(VLPs)
WO2012089231A1 (en) * 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
WO2013019800A1 (en) * 2011-08-01 2013-02-07 Emory University Vlps containing ligands and methods related thereto
JP6085886B2 (ja) 2011-08-29 2017-03-01 国立大学法人徳島大学 Ｒｓｖ粘膜ワクチン
RU2014117068A (ru) * 2011-09-30 2015-11-10 Новавакс, Инк. Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
KR102435054B1 (ko) 2012-08-01 2022-08-22 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신
EP2922570A1 (en) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
KR20150138184A (ko) * 2013-02-11 2015-12-09 노바백스, 인코포레이티드 호흡기 세포 융합 바이러스 및 인플루엔자를 위한 조합 백신
EP3798310A1 (en) * 2013-03-14 2021-03-31 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
DE102013004595A1 (de) * 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
BR112016006122B1 (pt) 2013-09-19 2023-11-14 Novavax, Inc COMPOSIÇÃO IMUNOGÊNICA COMPREENDENDO UMA NANOPARTÍCULA DO CORONAVÍRUS DA SÍNDROME RESPIRATÓRIA DO ORIENTE MÉDIO (MERS-CoV)
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
WO2015195961A1 (en) * 2014-06-18 2015-12-23 Georgia State University And Research Foundation, Inc. Recombinant rsv reporter virus
US9969986B2 (en) * 2014-08-08 2018-05-15 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
CA2996007A1 (en) * 2015-09-03 2017-03-09 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
MX2018005462A (es) 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.
RU2723039C2 (ru) 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
IL262108B2 (en) * 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V Soluble pre-fusion rsv f proteins are stabilized
CN109311946A (zh) 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
CN106011086A (zh) * 2016-06-15 2016-10-12 湖北省农业科学院畜牧兽医研究所 表达信号肽替换的呼吸道合胞病毒f蛋白的重组新城疫耐热疫苗株及制备方法
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
KR20260047644A (ko) 2017-03-30 2026-04-08 더 유니버서티 어브 퀸슬랜드 키메라 분자 및 그의 용도
HUE073526T2 (hu) 2017-04-04 2026-01-28 Univ Washington Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata
CA3066026A1 (en) 2017-06-14 2018-12-20 Virometix Ag Cyclic peptides for protection against respiratory syncytial virus
JP7317796B2 (ja) 2017-07-24 2023-07-31 ノババックス，インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
WO2019169120A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
CN120227451A (zh) 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
EP3775174A4 (en) * 2018-03-30 2022-07-06 Georgia State University Research Foundation, Inc. Respiratory syncytial virus (rsv) vaccines
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
EP3873517A4 (en) 2018-10-29 2022-09-28 Emory University RSV VIRUS-LIKE PARTICLES AND METHODS OF PRODUCTION THEREOF
KR102725189B1 (ko) * 2018-11-01 2024-10-31 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
JP7550762B2 (ja) 2018-12-20 2024-09-13 ヴァイロメティックス アーゲー リポペプチドビルディングブロックおよび合成ウイルス様粒子
EP3923983A4 (en) * 2019-02-11 2023-02-22 Emory University CHIMERIC RSV AND HMPV F PROTEINS, IMMUNOGENIC COMPOSITIONS AND METHODS OF USE
EP3932424A4 (en) 2019-02-28 2022-10-12 KM Biologics Co., Ltd. Rsv f/g chimeric vaccine
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20230070886A1 (en) * 2020-01-27 2023-03-09 Novavax, Inc. Coronavirus vaccine formulations
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
CN113855796B (zh) * 2021-07-30 2024-01-26 河北医科大学 卡介苗作为呼吸道合胞病毒灭活疫苗佐剂的应用
WO2023062651A1 (en) * 2021-10-13 2023-04-20 Padmanabh Patil Harshad Virus-like particles for respiratory syncytial virus and method of preparation thereof
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
US20240076320A1 (en) * 2022-09-01 2024-03-07 Novavax, Inc. Downstream process for purification of viral proteins with hydrophobic membrane domain for use in vaccine compositions
CN115927751B (zh) * 2022-09-17 2024-12-20 宁夏大学 牛呼吸道合胞体病毒实时荧光定量pcr检测的引物探针组及检测方法
JP2026510670A (ja) * 2023-03-17 2026-04-10 成都威斯克生物医▲薬▼有限公司 呼吸器合胞体ウイルス感染症に対するワクチン
WO2025026448A1 (zh) * 2023-08-03 2025-02-06 广州穗和生物技术有限公司 修饰的呼吸道合胞病毒f蛋白及其用途
CN119504955A (zh) * 2023-08-25 2025-02-25 深圳瑞吉生物科技有限公司 呼吸道合胞病毒抗原性多肽、核酸及疫苗
CN119569835A (zh) * 2023-09-07 2025-03-07 北京科兴中维生物技术有限公司 呼吸道合胞病毒f蛋白及其应用
US20250144200A1 (en) 2023-11-06 2025-05-08 Novavax, Inc. Intranasal immunogenic compositions
CN117645655B (zh) * 2024-01-26 2024-05-24 普大生物科技(泰州)有限公司 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法
WO2025201243A1 (zh) * 2024-03-25 2025-10-02 中国医学科学院医学生物学研究所 重组呼吸道合胞病毒融合前f蛋白突变体和其用途
CN118146321B (zh) * 2024-03-27 2024-08-27 普大生物科技(泰州)有限公司 一种rsv重组蛋白疫苗及其制备方法
CN118480560B (zh) 2024-07-09 2024-11-26 北京悦康科创医药科技股份有限公司 呼吸道合胞病毒mRNA疫苗及其制备方法和应用
CN119161422B (zh) * 2024-08-26 2026-04-03 扬州大学 一种呼吸道合胞病毒融合前f蛋白及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2243234C2 (ru) * 1996-07-12 2004-12-27 Коннот Лабораториз Лимитед Субъединичный вакцинный препарат респираторно-синцитиального вируса
EP1972348A1 (en) * 2007-03-14 2008-09-24 Pierre Fabre Medicament Novel vaccine composition for the treatment of respiratory infectious diseases
WO2008114149A2 (en) * 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
US20120093847A1 (en) * 2009-06-24 2012-04-19 Glaxosmithkline Biologicals Recombinant rsv vaccines

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
GB8914968D0 (en) * 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
NZ512980A (en) 1998-12-17 2003-07-25 Aventis Pasteur Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
JP5118798B2 (ja) 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
CZ2003930A3 (cs) 2000-10-02 2003-08-13 Glaxosmithkline Biologicals S. A. Vakcinační prostředek obsahující štěpený virus s obalem
US20040121465A1 (en) 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
EP1622574A4 (en) 2003-04-25 2006-10-18 Medimmune Vaccines Inc EXPRESSION SYSTEMS OF RECOMBINANT PARAINFLUENZA VIRUSES AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS DERIVED FROM METAPNEUMOVIRUS
US8541003B2 (en) * 2003-06-20 2013-09-24 Protein Sciences Corporation Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
US7588770B2 (en) 2003-12-10 2009-09-15 The Uab Research Foundation Recombinant viruses of the paramyxoviridae family with heterologous envelope glycoproteins
WO2007011396A2 (en) 2004-10-29 2007-01-25 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
CA2600484A1 (en) 2005-03-10 2006-09-21 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
CA2655929A1 (en) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins
WO2008061243A2 (en) 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
WO2008133663A2 (en) * 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
US20110008838A1 (en) 2007-07-19 2011-01-13 Gale Smith Chimeric varicella zoster virus virus-like particles
WO2009061334A1 (en) 2007-11-06 2009-05-14 Massachusetts Institute Of Technology Tissue-engineered endothelial and epithelial implants differentially and synergistically regulate tissue repair
JP5711972B2 (ja) 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えｒｓｖ抗原
WO2009108689A1 (en) 2008-02-25 2009-09-03 Novavax, Inc. Sugar glassified virus like particles (vlps)
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
PL2370099T3 (pl) 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
CA2768186A1 (en) * 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
KR101847908B1 (ko) 2010-11-05 2018-04-11 노바백스, 인코포레이티드 광견병 당단백질 바이러스-유사 입자(VLPs)
CN102107003A (zh) 2011-01-05 2011-06-29 重庆大学 一种猪繁殖与呼吸综合症病毒体疫苗及其制备方法
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
RU2014117068A (ru) 2011-09-30 2015-11-10 Новавакс, Инк. Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
KR20150138184A (ko) 2013-02-11 2015-12-09 노바백스, 인코포레이티드 호흡기 세포 융합 바이러스 및 인플루엔자를 위한 조합 백신
RU2531235C2 (ru) 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
KR102236497B1 (ko) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
AU2014100888A4 (en) 2014-08-07 2014-09-11 Novartis Ag Virus clearance and protein purification methods
WO2017000105A1 (zh) * 2015-06-29 2017-01-05 尚平 便携式加湿器
CA2996007A1 (en) 2015-09-03 2017-03-09 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2243234C2 (ru) * 1996-07-12 2004-12-27 Коннот Лабораториз Лимитед Субъединичный вакцинный препарат респираторно-синцитиального вируса
EP1972348A1 (en) * 2007-03-14 2008-09-24 Pierre Fabre Medicament Novel vaccine composition for the treatment of respiratory infectious diseases
WO2008114149A2 (en) * 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
US20120093847A1 (en) * 2009-06-24 2012-04-19 Glaxosmithkline Biologicals Recombinant rsv vaccines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CS195596 SV 1; linear; protein; PRT; VRL; 574 AA. 01-DEC-2005 Sequence 3 from Patent WO2005080417. CQ753498; SV 1; linear; protein; PRT; VRL; 574 AA.XX. 01-MAR-2004.Sequence 1 from Patent WO2004001425. *

Also Published As

Publication number Publication date
BRPI0922867B8 (pt) 2021-05-25
US20150266930A1 (en) 2015-09-24
MX2011006205A (es) 2011-09-01
KR20160148720A (ko) 2016-12-26
WO2010077717A1 (en) 2010-07-08
SI2370099T1 (sl) 2016-08-31
IL213450A0 (en) 2011-07-31
HK1161690A1 (zh) 2012-08-03
US9731000B2 (en) 2017-08-15
JP2012511579A (ja) 2012-05-24
MX358836B (es) 2018-09-05
CA2746228C (en) 2021-05-18
HRP20160859T1 (hr) 2016-09-23
US12357684B2 (en) 2025-07-15
KR20110112328A (ko) 2011-10-12
CN106146671A (zh) 2016-11-23
RU2011128371A (ru) 2013-01-20
JP6782289B2 (ja) 2020-11-11
US20230293667A1 (en) 2023-09-21
PT2370099T (pt) 2016-07-14
BRPI0922867B1 (pt) 2020-09-29
EP2370099B1 (en) 2016-04-20
KR101691574B1 (ko) 2017-01-02
CN102307591A (zh) 2012-01-04
PL2370099T3 (pl) 2016-10-31
SI3067064T1 (sl) 2020-09-30
AU2009333484A1 (en) 2011-07-21
EP2370099A4 (en) 2013-05-29
EP3718566B1 (en) 2024-06-12
SMT202000411T1 (it) 2020-09-10
KR101801213B1 (ko) 2017-11-24
PT3067064T (pt) 2020-06-16
JP2015171378A (ja) 2015-10-01
PL3067064T3 (pl) 2020-11-02
EP3067064A1 (en) 2016-09-14
ES2987238T3 (es) 2024-11-14
US20100239617A1 (en) 2010-09-23
US10022437B2 (en) 2018-07-17
AU2009333484B2 (en) 2014-12-11
US20150359872A1 (en) 2015-12-17
HRP20200871T1 (hr) 2020-10-30
EP3718566A1 (en) 2020-10-07
HUE051666T2 (hu) 2021-03-29
JP2018007655A (ja) 2018-01-18
JP5813513B2 (ja) 2015-11-17
CN106146671B (zh) 2020-03-31
EP2370099A1 (en) 2011-10-05
IL247341B (en) 2018-04-30
CY1117757T1 (el) 2017-05-17
US9717786B2 (en) 2017-08-01
CN102307591B (zh) 2016-08-03
US20150265698A1 (en) 2015-09-24
HUE029037T2 (en) 2017-01-30
BRPI0922867A2 (pt) 2016-09-27
US20140294879A1 (en) 2014-10-02
US8715692B2 (en) 2014-05-06
JP2019069982A (ja) 2019-05-09
DK3067064T3 (da) 2020-06-08
MX337932B (es) 2016-03-28
JP6462048B2 (ja) 2019-01-30
JP6162751B2 (ja) 2017-07-12
LT3067064T (lt) 2020-09-10
ES2582005T3 (es) 2016-09-08
DK2370099T3 (en) 2016-08-01
CA2746228A1 (en) 2010-07-08
ES2796725T3 (es) 2020-11-30
IL213450B (en) 2018-02-28
CY1123152T1 (el) 2021-10-29
US11052146B2 (en) 2021-07-06
SG10201500161XA (en) 2015-03-30
MX345700B (es) 2017-02-10
SG172022A1 (en) 2011-07-28
US9675685B2 (en) 2017-06-13
EP3067064B1 (en) 2020-05-13
US20190134187A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
US12357684B2 (en) Modified RSV F proteins and methods of their use
US20170319682A1 (en) Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
US11446374B2 (en) Modified RSV F proteins and methods of their use
HK1228754B (en) Modified rsv f proteins and methods of their use
HK1161690B (en) Modified rsv f proteins and methods of their use
HK1228754A1 (en) Modified rsv f proteins and methods of their use